# US 2021/0275550 A1 · Drink product containing genistein and use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0275550 A1
- Document ID: US20210275550A1
- Status: Published application
- Kind: A1
- Application number: 17/330,223
- Filed: 2021-05-25
- Published: 2021-09-09
- Earliest claimed: 2013-03-14
- Assignees: Hygia Pharmaceuticals, LLC
- Applicants: Hygia Pharmaceuticals, LLC
- Inventors: Barbara Brooke Jennings
- Web page: https://patentgrep.com/patent/US20210275550A1

## CPC

- A61K 31/6615: Compounds having two or more esterified phosphorus acid groups, e.g. inositol triphosphate, phytic acid
- A23L 2/52: Adding ingredients (adding preservatives A23B70/10)
- A23L 33/40: {Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula}
- A61K 9/0095: {Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches (A61K9/0007 takes precedence; eatable gels or foams A61K9/0056; oral mucosa adhesive forms A61K9/006)}
- A61K 31/047: having two or more hydroxy groups, e.g. sorbitol
- A61K 31/09: having two or more such linkages
- A61K 31/352: condensed with carbocyclic rings, e.g. methantheline {(cannabinoids A61K31/658)}
- A61K 31/661: Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion {or mevinphos}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 47/12: Carboxylic acids; Salts or anhydrides thereof
- A61K 47/22: Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
- A61K 47/26: Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A61P 39/06: Free radical scavengers or antioxidants
- A23V 2002/00: Food compositions, function of food ingredients or processes for food or foodstuffs
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A23L: FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF (preservation thereof A23B)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A23V: INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION

## Abstract

A drink product having as an active ingredient genistein and an inositol hexaphosphate and/or an unphosphorylated inositol and optionally additional inositol (unphosphorylated as well as hexaphosphorylated) moieties. Hexaphosphates for use in the invention include myoinositol hexaphosphate and/or any of the other 8 optical isomers thereof. The optional additional inositols include myoinositol and/or any of the other 8 optical isomers thereof. Uses for prevention, treatment, and reduction in risk of developing or progression of a number of conditions are disclosed.

## Claims

### Claim 1

An aqueous liquid formulation comprising:
(a) water and
(b) myoinositol hexaphosphate and/or an optical isomer thereof, and/or an orally acceptable salt thereof,
(c) Genistein
(d) further optionally comprising one or more components selected from the group consisting of:
(1) myoinositol and/or optical isomer;
(2) an orally acceptable free radical scavenger other than Genistein;
(3) a nutritionally acceptable orally administrable electrolyte;
(4) a nutritionally acceptable orally administrable vitamin;
(5) a flavor;
(6) an orally administrable coloring agent;
(7) an orally administrable sweetener;
(8) an oral formulation acceptable thickener;
(9) an orally administrable, liquid formulation processing aid; and,
(10) an orally administrable, liquid formulation auxiliary carrier other than water.

### Claim 2 (depends on 1)

A method of reducing the risk of damage to cells or tissues due to reactive oxygen species free radicals in a subject in need thereof comprising orally administering the formulation of claim 1.

### Claim 3 (depends on 1)

A method of preventing damage to cells or tissues due to reactive oxygen species free radicals in a subject in need thereof comprising orally administering the formulation of claim 1.

### Claim 4 (depends on 1)

A method of treating damage to cells or tissues due to reactive oxygen species free radicals in a subject in need thereof comprising orally administering the formulation of claim 1.

### Claim 5 (depends on 1)

A method of reducing the risk of developing HIV and/or AIDS and secondary cancers related to HIV and AIDS comprising orally administering the formulation of claim 1.

### Claim 6 (depends on 5)

The method of claim 5 wherein said cancers related to HIV and AIDS is selected from Kaposi sarcoma and non-Hodgkin lymphoma, Hodgkin disease and cancers of the lung, mouth, skin, cervix, and digestive system, liver, blood, soft tissue, and muscular tumors.

### Claim 7 (depends on 1)

A method of preventing a HIV/AIDS related cancer selected from breast, pancreatic, ovarian, prostate, lung cancer, skin cancer, colon cancer liver, cervical, uterine, liver, blood, soft tissue, and muscular tumors in a subject in need thereof comprising orally administering the formulation of claim 1.

### Claim 8 (depends on 1)

A method of treating a cancer selected from Kaposi sarcoma and non-Hodgkin lymphoma, other AIDS-related cancers selected from Hodgkin disease and cancers of the lung, mouth, skin, cervix, and digestive system, liver blood, soft tissue, and muscular tumors breast, pancreatic, ovarian, prostate, lung cancer, skin cancer, coln cancer liver, cervical, uterine, liver, blood, soft tissue, and muscular tumors in a subject in need thereof comprising orally administering the formulation of claim 1.

### Claim 9 (depends on 1)

A method of increasing T cells and or inhibiting HIV related CD4 reduction comprising administering the composition of claim 1 to a subject in need thereof

### Claim 10 (depends on 1)

A method for blocking the communication between a HIV cell surface to internal cellular compartment comprising administering the composition of claim 1 to a subject in need thereof.

### Claim 11 (depends on 1)

A method for preventing an HIV particle from entering the internal cellular compartments thereby preventing the spread of the infection comprising administering the composition of claim 1 to a subject in need thereof.

### Claim 12 (depends on 1)

A method of reducing the risk of adverse effects of common and current drug toxicities' associated with current anti-viral therapies comprising administering the composition of claim 1 to a subject in need thereof.

### Claim 13 (depends on 1)

A method of reducing drug resistance comprising administering the composition of claim 1 to a subject in need thereof.

### Claim 14 (depends on 1)

A method for both prevention HIV infection of resting CD4 T-cells, viral DNA synthesis, and/or viral nuclear migration comprising administering the composition of claim 1 to a subject in need thereof.

### Claim 15 (depends on 1)

A method for preventing Gag-Na inositol does that interactions prior to membrane binding in HIV comprising administering the composition of claim 1 to a subject in need thereof.

### Claim 16 (depends on 1)

A method for inhibiting the replication of HIV-1 comprising administering the composition of claim 1 to a subject in need thereof

### Claim 17 (depends on 1)

A method for AP3B1 regulation and HIV-1 Gag release comprising administering the composition of claim 1 to a subject in need thereof.

### Claim 18 (depends on 1)

The product of claim 1 which is a liquid nutritional supplement.

### Claim 19 (depends on 1)

The product of claim 1 which is an orally administered product.

### Claim 20 (depends on 1)

A method of reducing the risk of damage to cells or tissues due to reactive oxygen species free radicals in a subject in need thereof comprising orally administering the formulation of claim 1.

### Claim at position 21

21-30. (canceled)